FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379649993> ?p ?o ?g. }

• W4379649993 endingPage "910" @default.
• W4379649993 startingPage "910" @default.
• W4379649993 abstract "Background Antiphospholipid syndrome (APS) is a syndrome which consists of vascular thrombotic events, arterial or venous, with the presence of persistent circulating antibodies. APS patients have a highly variable risk profile, derived from their different medical risk factors and diverse antiphospholipid antibodies (aPL) profile. The current mainstay for the treatment of APS is anticoagulation with Vitamin K antagonists (VKAs). The primacy of Warfarin has been challenged by the introduction of direct oral anticoagulants (DOACs), stems from DOACs convenience, constant dosing, without the need for blood test monitoring and almost no drug interactions. However, the TRAPS study that compared Rivaroxaban to Warfarin treatment in APS patients was terminated prematurely due to higher incidence of thrombotic events in the Rivaroxaban group [1]. Yet, all patients on the TRAPS trial were triple-aPL positive. Similar conclusions were demonstrated on the ASTRO study that compared Apixaban to Warfarin treatment [2]. Because the risk profile of APS patients is heterogeneous, both clinically and serologically, it is difficult to conclude that treatment with DOACs is generally inferior to VKAs for all APS patients, for instance in the low-risk patient population. Objectives We assume that under real-life circumstances, VKAs narrow therapeutic range and the constant need for repeated INR checkups may change the above studies outcomes. Hereby, the aim of this study is to compare real-life outcomes of APS patients treated with DOACs to patients treated with Warfarin from the aspect of thrombotic events reoccurrence on one hand and bleeding events on the other hand. We also checked the outcomes specifically for different APS risk profile subgroups under different treatments with either Warfarin or DOACs. Methods 139 non obstetric APS patients from “Meir” medical center were followed up retrospectively for a mean period of 16 years, since diagnosis time until 31/12/2022. We gathered data on patients SLE status, aPL profile and type of thrombotic event at the time of diagnosis. We checked for thrombotic events reoccurrence and bleeding events (including their types) with respect to the specific treatment at the time of each event. Results Of 139 followed-up patients, we report a total of 217 thrombotic and 60 bleeding events. From the Warfarin treated group, 178 (82%) thrombotic events were recorded, 130 (74%) of them occurred in the high risk serological profile patients. From the DOACs treated group, 39 (18%) thrombotic event were recorded, 23 (59%) of them occurred in the high risk serological profile patients. 59 (98%) bleeding events were recorded in the Warfarin treated group, 46 (82%) among the high risk profile group. only one bleeding event was recorded in the DOACs group. Conclusion According to our single center data gathered retrospectively form a follow up of real- life APS patient’s treatment, Warfarin vs DOACs, we found higher incidence of thrombotic events (82%) in the Warfarin group compared to the DOACs group (59%). High risk profile patients had a higher thrombotic incidence in both groups. Moreover, patients taking Warfarin had a dramatically higher incidence of bleeding events comparing to DOACs (98% vs 0.01% respectively). These findings may raise the differences between real-life and controlled researches and may challenge the superiority of Warfarin. More researches are needed in order to answer this question. References [1]Pengo, V, Hoxha, A, Andreoli, L, et al. Trial of Rivaroxaban in Antiphospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. J Thromb Haemost . 2021; 19: 531– 535. https://doi.org/10.1111/jth.15158 [2]Woller SC, Stevens SM, Kaplan DA, et al. Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome: study rationale and design (ASTRO-APS). Clin Appl Thromb Hemost 2016; 22: 239–247. Acknowledgements: NIL. Disclosure of Interests None Declared." @default.
• W4379649993 created "2023-06-08" @default.
• W4379649993 creator A5022802378 @default.
• W4379649993 creator A5039104816 @default.
• W4379649993 creator A5092107191 @default.
• W4379649993 date "2023-05-30" @default.
• W4379649993 modified "2023-09-26" @default.
• W4379649993 title "POS1157 WARFARIN VS DOACS IN A REAL-WORLD DATA" @default.
• W4379649993 doi "https://doi.org/10.1136/annrheumdis-2023-eular.6069" @default.
• W4379649993 hasPublicationYear "2023" @default.
• W4379649993 type Work @default.
• W4379649993 citedByCount "0" @default.
• W4379649993 crossrefType "journal-article" @default.
• W4379649993 hasAuthorship W4379649993A5022802378 @default.
• W4379649993 hasAuthorship W4379649993A5039104816 @default.
• W4379649993 hasAuthorship W4379649993A5092107191 @default.
• W4379649993 hasBestOaLocation W43796499931 @default.
• W4379649993 hasConcept C120665830 @default.
• W4379649993 hasConcept C121332964 @default.
• W4379649993 hasConcept C126322002 @default.
• W4379649993 hasConcept C2776301958 @default.
• W4379649993 hasConcept C2776874634 @default.
• W4379649993 hasConcept C2777288759 @default.
• W4379649993 hasConcept C2778205648 @default.
• W4379649993 hasConcept C2778661090 @default.
• W4379649993 hasConcept C2779161974 @default.
• W4379649993 hasConcept C2780638905 @default.
• W4379649993 hasConcept C2780868729 @default.
• W4379649993 hasConcept C2908647359 @default.
• W4379649993 hasConcept C61511704 @default.
• W4379649993 hasConcept C71924100 @default.
• W4379649993 hasConcept C99454951 @default.
• W4379649993 hasConceptScore W4379649993C120665830 @default.
• W4379649993 hasConceptScore W4379649993C121332964 @default.
• W4379649993 hasConceptScore W4379649993C126322002 @default.
• W4379649993 hasConceptScore W4379649993C2776301958 @default.
• W4379649993 hasConceptScore W4379649993C2776874634 @default.
• W4379649993 hasConceptScore W4379649993C2777288759 @default.
• W4379649993 hasConceptScore W4379649993C2778205648 @default.
• W4379649993 hasConceptScore W4379649993C2778661090 @default.
• W4379649993 hasConceptScore W4379649993C2779161974 @default.
• W4379649993 hasConceptScore W4379649993C2780638905 @default.
• W4379649993 hasConceptScore W4379649993C2780868729 @default.
• W4379649993 hasConceptScore W4379649993C2908647359 @default.
• W4379649993 hasConceptScore W4379649993C61511704 @default.
• W4379649993 hasConceptScore W4379649993C71924100 @default.
• W4379649993 hasConceptScore W4379649993C99454951 @default.
• W4379649993 hasIssue "Suppl 1" @default.
• W4379649993 hasLocation W43796499931 @default.
• W4379649993 hasOpenAccess W4379649993 @default.
• W4379649993 hasPrimaryLocation W43796499931 @default.
• W4379649993 hasRelatedWork W2033241806 @default.
• W4379649993 hasRelatedWork W2141461219 @default.
• W4379649993 hasRelatedWork W2576538605 @default.
• W4379649993 hasRelatedWork W2724472742 @default.
• W4379649993 hasRelatedWork W2728054236 @default.
• W4379649993 hasRelatedWork W2741829680 @default.
• W4379649993 hasRelatedWork W2895090492 @default.
• W4379649993 hasRelatedWork W2908436399 @default.
• W4379649993 hasRelatedWork W2929067776 @default.
• W4379649993 hasRelatedWork W2929832413 @default.
• W4379649993 hasVolume "82" @default.
• W4379649993 isParatext "false" @default.
• W4379649993 isRetracted "false" @default.
• W4379649993 workType "article" @default.